Karen A. Dawes, Director at REPLIGEN CORP (RGEN), sold 10,377 shares at $280.27 ($2.1M) on 2021-09-01, disclosed to the SEC on 2021-09-02.
Open-market sale of $2.1M RGEN by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $38.76 | 3,459 | $134K | 6.4% |
| 2 | $280.27 | 239 | $67K | 3.2% |
| 3 | $280.27 | 239 | $67K | 3.2% |
| 4 | $281.68 | 196 | $55K | 2.6% |
| 5 | $281.68 | 196 | $55K | 2.6% |
| 6 | $282.53 | 405 |
| $114K |
| 5.5% |
| 7 | $282.53 | 405 | $114K | 5.5% |
| 8 | $283.56 | 661 | $187K | 8.9% |
| 9 | $283.56 | 661 | $187K | 8.9% |
| 10 | $284.64 | 1,107 | $315K | 15.0% |
| 11 | $284.64 | 1,107 | $315K | 15.0% |
| 12 | $285.44 | 851 | $243K | 11.6% |
| 13 | $285.44 | 851 | $243K | 11.6% |
| Total | $202.20 avg | 10,377 | $2.1M | 100% |
| Filing → |
| RGEN | SELL | 2023-08-30 | $146K | — | Filing → |
| RGEN | SELL | 2022-09-09 | $352K | — | Filing → |
| RGEN | SELL | 2022-05-26 | $4.4M | — | Filing → |